Truist cuts ArriVent BioPharma price target to $18
Truist Securities cut its ArriVent BioPharma price target to $18.00 per share from $45.00, per Benzinga ratings action coverage.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Truist Securities cuts ArriVent BioPharma price target to $18
Truist Securities reduced its ArriVent BioPharma price target to $18.00 per share from $45.00, according to Benzinga ratings actions.
Allstate, Caribou Biosciences, Zscaler: analyst rating changes
HSBC raises Allstate to buy from hold. RBC cuts Caribou Biosciences to sector perform from outperform. Jefferies raises Zscaler target price to $250 from $220.